ライフサイエンスコーパス: romiplostim

1 ective trial evaluated treatment of CIT with romiplostim.

2 romiplostim resumed chemotherapy with weekly romiplostim.

3 o normal values by the thrombopoietin-analog romiplostim.

4 77 patients [30%], P<0.001) (odds ratio with romiplostim, 0.31; 95% CI, 0.15 to 0.61).

5 87% (20/23) of patients given romiplostim (12/12 splenectomised and eight of 11 non-sp

6 formed less frequently in patients receiving romiplostim (14 of 157 patients [9%]) than in those rece

7 tients) or weekly subcutaneous injections of romiplostim (157 patients).

8 (< 50 vs >/= 50 x 10(9)/L) and randomized to romiplostim 500 mug or 750 mug or placebo subcutaneously

9 hrombocytopenic events in patients receiving romiplostim 500 mug, romiplostim 750 mug, or placebo was

10 4 (IQR, 2-5), including eltrombopag (76.1%), romiplostim (57.2%), and IV immunoglobulins (44.2%).

11 Romiplostim 750 mug significantly raised median platelet

12 s in patients receiving romiplostim 500 mug, romiplostim 750 mug, or placebo was 62%, 71%, and 85%, r

13 We evaluated the efficacy and safety of romiplostim, a thrombopoietin mimetic, in patients with

14 Romiplostim, a thrombopoietin mimetic, increases platele

15 Romiplostim, a thrombopoietin-mimetic peptibody, increas

16 Patients given romiplostim achieved platelet counts of 50x10(9)/L or mo

17 In previous studies romiplostim (AMG531), a thrombopoiesis-stimulating prote

18 4, 62 patients were randomly assigned; 42 to romiplostim and 20 to placebo.

19 red in 23% of patients (35 of 154) receiving romiplostim and 37% of patients (28 of 75) receiving the

20 Platelet responses to romiplostim and eltrombopag are seen in a much greater p

21 Two agents, romiplostim and eltrombopag, are now licensed and their

22 events were much the same in patients given romiplostim and placebo.

23 ed as no response to splenectomy, rituximab, romiplostim, and eltrombopag.

24 Romiplostim appeared well-tolerated in this study and ma

25 ry objectives were to assess the efficacy of romiplostim as measured by a durable platelet response (

26 The median weekly dose of romiplostim at 12 weeks was 5 mug/kg.

27 jections of 300, 700, 1,000, or 1,500 microg romiplostim at weekly intervals.

28 Leon and colleagues describe the effects of romiplostim, athrombopoietin (Tpo) mimetic peptide, in t

29 Durable platelet response rates with romiplostim by age were 38% (3/8) for 1 year to younger

30 Of 271 ITP patients in romiplostim clinical trials, 10 were reported to have re

31 79% (33/42) of splenectomised patients given romiplostim compared with 14% (three of 21) of non-splen

32 The thrombopoietin receptor agonist romiplostim could be an effective treatment in symptomat

33 Prolonged (but not acute) treatment with romiplostim decreased expression of GPIb-IX-V complex an

34 Reticulin grade often decreased soon after romiplostim discontinuation.

35 In 77% of patients, the romiplostim dose remained within 2 microg/kg of their mo

36 Fourteen responders received romiplostim for 4 additional weeks for assessment of pha

37 was achieved by 15/17 (88%) patients in the romiplostim group and no patients in the placebo group (

38 esponse was seen in 22 (52%) patients in the romiplostim group and two (10%) in the placebo group (p=

39 The romiplostim group had a lower rate of bleeding events, f

40 The rate of a platelet response in the romiplostim group was 2.3 times that in the standard-of-

41 bocytosis, in one (2%) of 42 patients in the romiplostim group, were considered treatment related.

42 compared with 10 (24%) of 42 patients in the romiplostim group.

43 Patients treated with romiplostim had a higher rate of a platelet response, lo

44 Patients receiving romiplostim had a significantly lower incidence of treat

45 n of the thrombopoiesis-stimulating protein, romiplostim, has been shown to increase platelet counts

46 t week 4, patients could continue to receive romiplostim in a treatment extension phase for up to 1 y

47 We assessed the long-term administration of romiplostim in splenectomised and non-splenectomised pat

48 In this short-term study, romiplostim increased platelet counts in 88% of children

49 In conclusion, romiplostim increased platelet counts in most patients f

50 ildren with chronic immune thrombocytopenia, romiplostim induced a high rate of platelet response wit

51 Romiplostim is a thrombopoietin receptor agonist that in

52 Romiplostim is a TPO peptide mimetic given by subcutaneo

53 Romiplostim is effective in correcting CIT, and maintena

54 We aimed to assess whether romiplostim is safe and effective in children with immun

55 rospective analysis of reticulin observed in romiplostim ITP clinical trials, and a prospective clini

56 Stimulation of platelet production by romiplostim may provide a new therapeutic option for pat

57 This study suggests romiplostim may provide clinical benefits in MDS patient

58 Children received subcutaneous injections of romiplostim (n = 17) or placebo (n = 5) weekly for 12 we

59 ) treated with either eltrombopag (n = 8) or romiplostim (n = 7) during pregnancy, including 2 patien

60 y assigned 2:1 to subcutaneous injections of romiplostim (n=42 in splenectomised study and n=41 in no

61 prospective clinical study of the effects of romiplostim on bone marrow morphology.

62 No neutralizing antibodies to either romiplostim or endogenous thrombopoietin were seen.

63 tive voice response system to receive weekly romiplostim or placebo for 24 weeks stratified by age (1

64 No antibodies against romiplostim or thrombopoietin were detected.

65 ned for a median of 7 (range, 0-11) weeks in romiplostim patients and 0 (0-0) weeks in placebo patien

66 al 37 patients were treated in a single-arm, romiplostim phase.

67 In rats, romiplostim produced a dose-dependent increase in bone m

68 This report suggests that romiplostim produces reversible, dose-dependent bone mar

69 Reduction of GPIbIX/GPVI expression by romiplostim requires further studies.

70 tients who achieved platelet correction with romiplostim resumed chemotherapy with weekly romiplostim

71 rombopoietin receptor agonists (eltrombopag; romiplostim) seem to improve hemostasis, but little is k

72 Ongoing romiplostim studies will provide further information as

73 fficacy in patients who completed a previous romiplostim study and had platelet counts less than or e

74 We administered romiplostim to Myh9(-/-) mice (100 mug/kg, every 3 days,

75 atment with the thrombopoietin (TPO) mimetic romiplostim (TPO(high)).

76 rash and arthralgia each were reported in 1 romiplostim-treated patient (4%).

77 In the randomization phase, 14 of 15 romiplostim-treated patients (93%) experienced correctio

78 Including all romiplostim-treated patients (N = 52), the mean platelet

79 months, 82.5% and 74.3% of eltrombopag- and romiplostim-treated patients, respectively, achieved a r

80 s report describes bone marrow findings from romiplostim-treated rats, a retrospective analysis of re

81 he prospective study, reticulin grade during romiplostim treatment remained within the normal range f

82 eticulin fibers was present after 4 weeks of romiplostim treatment vs WT mice.

83 We conducted a phase II randomized trial of romiplostim versus untreated observation in patients wit

84 Romiplostim was well tolerated, and increased and mainta

85 Patients received weekly titrated romiplostim with a target platelet count of 100,000/muL